Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs

Mahmoud Al Rifai; Dhruv Mahtta; David J. Ramsey; Michelle T. Lee; Chayakrit Krittanawong; Sankar D. Navaneethan; L. Parker Gregg; Laura A. Petersen; Salim S. Virani

doi:10.1016/j.ahj.2021.12.006

Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs

Mahmoud Al Rifai, Dhruv Mahtta, David J. Ramsey, Michelle T. Lee, Chayakrit Krittanawong, Sankar D. Navaneethan, L. Parker Gregg, Laura A. Petersen, Salim S. Virani

Research output: Contribution to journal › Letter › peer-review

6 Scopus citations

Abstract

This study using data from the Veterans Affairs (VA) administrative and clinical dataset examined determinants of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use among patients with concomitant atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus. The aim of the present analysis was to identify barriers and facilitators associated with SGLT-2i in a real-world contemporary patient population in order to improve utilization of these guideline-directed agents.

Original language	English (US)
Pages (from-to)	160-162
Number of pages	3
Journal	American Heart Journal
Volume	248
DOIs	https://doi.org/10.1016/j.ahj.2021.12.006
State	Published - Jun 2022

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.ahj.2021.12.006

Cite this

Al Rifai, M., Mahtta, D., Ramsey, D. J., Lee, M. T., Krittanawong, C., Navaneethan, S. D., Gregg, L. P., Petersen, L. A., & Virani, S. S. (2022). Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs. American Heart Journal, 248, 160-162. https://doi.org/10.1016/j.ahj.2021.12.006

Al Rifai, M, Mahtta, D, Ramsey, DJ, Lee, MT, Krittanawong, C, Navaneethan, SD, Gregg, LP, Petersen, LA & Virani, SS 2022, 'Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs', American Heart Journal, vol. 248, pp. 160-162. https://doi.org/10.1016/j.ahj.2021.12.006

@article{b730a96f563e4880b2a803bc25500f7a,

title = "Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs",

abstract = "This study using data from the Veterans Affairs (VA) administrative and clinical dataset examined determinants of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use among patients with concomitant atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus. The aim of the present analysis was to identify barriers and facilitators associated with SGLT-2i in a real-world contemporary patient population in order to improve utilization of these guideline-directed agents.",

author = "{Al Rifai}, Mahmoud and Dhruv Mahtta and Ramsey, {David J.} and Lee, {Michelle T.} and Chayakrit Krittanawong and Navaneethan, {Sankar D.} and Gregg, {L. Parker} and Petersen, {Laura A.} and Virani, {Salim S.}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2022",

month = jun,

doi = "10.1016/j.ahj.2021.12.006",

language = "English (US)",

volume = "248",

pages = "160--162",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus

T2 - Insights from the department of veterans affairs

AU - Al Rifai, Mahmoud

AU - Mahtta, Dhruv

AU - Ramsey, David J.

AU - Lee, Michelle T.

AU - Krittanawong, Chayakrit

AU - Navaneethan, Sankar D.

AU - Gregg, L. Parker

AU - Petersen, Laura A.

AU - Virani, Salim S.

PY - 2022/6

Y1 - 2022/6

N2 - This study using data from the Veterans Affairs (VA) administrative and clinical dataset examined determinants of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use among patients with concomitant atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus. The aim of the present analysis was to identify barriers and facilitators associated with SGLT-2i in a real-world contemporary patient population in order to improve utilization of these guideline-directed agents.

AB - This study using data from the Veterans Affairs (VA) administrative and clinical dataset examined determinants of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use among patients with concomitant atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus. The aim of the present analysis was to identify barriers and facilitators associated with SGLT-2i in a real-world contemporary patient population in order to improve utilization of these guideline-directed agents.

UR - http://www.scopus.com/inward/record.url?scp=85126541154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126541154&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2021.12.006

DO - 10.1016/j.ahj.2021.12.006

M3 - Letter

C2 - 34968441

AN - SCOPUS:85126541154

SN - 0002-8703

VL - 248

SP - 160

EP - 162

JO - American Heart Journal

JF - American Heart Journal

ER -

Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this